{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'three features, it should be primarily determined by the degree of erythema, as that is', 'the dominant feature in the majority of cases of genital psoriasis (Merola, 2017).', 'Appendix F.', '6.4.6.', 'Palmoplantar Psoriasis Physicians Global Assessment (PPPGA)', 'The PPPGA is the assessment by the Investigator of the overall disease severity at the', 'time of evaluation of palms and soles (Leonardi, 2007). The scale ranges from', 'ranging from 0 (clear) to 4 (severe). See Appendix G.', '6.4.7.', 'Itch Numeric Rating Scale (NRS)', 'The Itch NRS is a single-item patient-reported outcome that asks subjects to assess', 'the worst severity of itch over the past 24 hours. Subjects indicate itch severity by', 'circling the number that best describes the worst level of itching due to psoriasis in', 'the past 24 hours on an 11-point scale anchored at 0, representing \"no itching\\' and 10,', 'representing \"worst itch imaginable\\' (Naegeli, 2015). See Appendix H.', '6.4.8.', 'Skin Discomfort/Pain Visual Analog Scale (VAS)', 'The subject will be asked to place a vertical stroke on a 100 mm VAS on which the', 'left-hand boundary represents no skin discomfort/pain, and the right-hand boundary', 'represents skin discomfort/pain as severe as can be imagined. The distance from the', 'mark to the left-hand boundary will be recorded. See Appendix I.', '6.4.9.', 'Body Surface Area (BSA)', 'Body surface area is a measurement of involved skin. The overall BSA affected by', \"psoriasis is estimated based on the palm area of the subject's hand (entire palmar\", 'surface or \"handprint\"), which equates to approximately 1% of total BSA.', '6.4.10.', 'Psoriasis Area Severity Index (PASI)', 'The PASI will be determined for all subjects throughout the study. The PASI', 'calculation is described in Appendix J.', 'The PASI is a measure of psoriatic disease severity taking into account qualitative', 'lesion characteristics (erythema, thickness, and scaling) and degree of skin surface', 'area involvement on defined anatomical regions. The PASI is a validated instrument', 'that has become standard in clinical trials for psoriasis.', 'The PASI scores range from 0 to 72, with higher scores reflecting greater disease', 'severity (Fredriksson, 1978). Erythema, thickness, and scaling are scored on a scale', 'of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper', 'limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is', 'scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total', 'qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the', 'degree of involvement for each anatomic region and then multiplied by a constant.', 'These values for each anatomic region are summed to yield the PASI score.', 'Confidential and Proprietary', '36', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '6.4.11.', 'Patient Benefit Index (PBI)', 'The PBI is a validated patient-reported instrument to assess patient-relevant benefits', 'of psoriasis treatment (Feuerhahn, 2012). Prior to starting therapy, subjects are asked', 'to assess their treatment expectations by completing the Patient Needs Questionnaire', '(PNQ) (See Appendix K). After a period of treatment, subjects are then asked to', 'assess the benefits of treatment by completing the Patient Benefit Questionnaire', '(PBQ) (See Appendix L). The Patient Benefit Index represents the subject benefits', 'realized as a function of most important subject needs. The PBI score ranges from 0', '(no benefit) to 4 (maximum benefit).', '6.4.12.', 'The European Quality of Life 5-Dimension Questionnaire (EQ-5D)', \"EQ-5D (The EuroQol Group, 1990) measures the subject's general health state as a\", 'vertical VAS and 5 quality of life domains as multiple-choice questions: mobility,', 'self-care, main activity (work, study, housework, family/leisure activities),', 'pain/discomfort, and anxiety/depression, the combination of which generates 243', 'possible health states. See Appendix M.', '6.4.13.', 'The Work Productivity and Activity Impairment Questionnaire: Psoriasis', '(WPAI: PSO)', 'The WPAI: PSO questionnaire is a validated, 6-item self-administered instrument', 'used to assess the impact of disease on work productivity in psoriasis due to general', 'health or a specified health problem (Reilly, 2012; Appendix N).', '6.4.15.', 'Photography', 'Photographs will be collected only at selected sites, in subjects who consent, and will', 'be considered as supportive evidence of efficacy. Descriptive summary of', 'photography will be addressed in the statistical analysis plan (SAP) and included in', 'the clinical study report.', 'Confidential and Proprietary', '37', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}